IGC Pharma (IGC) Invested Capital (2011 - 2026)

IGC Pharma (IGC) has 16 years of Invested Capital data on file, last reported at $6.1 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $6.1 million, down 2.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.1 million (down 2.88% YoY), and the FY2026 annual result was $6.1 million, down 2.88% from the prior year.
• Invested Capital fell to $6.1 million in Q1 2026 per IGC's latest filing, from $7.6 million in the prior quarter.
• Over five years, Invested Capital peaked at $23.9 million in Q1 2022 and troughed at $6.1 million in Q2 2025.
• A 5-year average of $11.7 million and a median of $8.1 million in 2025 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2024 and 2025: Invested Capital slumped 50.9% in 2024, then advanced 21.47% in 2025.
• A 5-year view of Invested Capital shows it stood at $18.3 million in 2022, then plunged by 50.58% to $9.1 million in 2023, then plunged by 30.86% to $6.3 million in 2024, then rose by 21.47% to $7.6 million in 2025, then decreased by 19.14% to $6.1 million in 2026.
• Business Quant data shows IGC's Invested Capital at $6.1 million in Q1 2026, $7.6 million in Q4 2025, and $8.1 million in Q3 2025.